Formulation Development
First Patient Enrolled in Investigator-Initiated Trial With OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
Oculis Holding AG recently announced the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ novel…
KBio & ZERO Announce Exclusive Strategic Alliance to Develop a Globally Distributed & Rapidly Deployable Plant-Based Molecular Farming Network
KBio and ZERO recently announced an exclusive strategic alliance to build the world’s first transportable globally distributed plant-based molecular farming network to include therapeutic, pandemic…
ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets
ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….
IntelGenx Completes Enrollment for BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild-to-Moderate Alzheimer’s Disease
IntelGenx Corp. recently announced it has completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a (BUENA) clinical trial in patients with mild-to-moderate Alzheimer’s Disease…
Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….
Avenue Therapeutics Announces High Potency & Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator Supporting Phase 2 Clinical Study
Avenue Therapeutics, Inc. recently announced BAER-101, the company’s potentially best-in-class selective GABA-A α2,3 positive allosteric modulator (PAM), significantly suppressed seizures in a translational animal model…
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
AltruBio Inc. recently announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in healthy volunteers. “We…
WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development
This white paper describes use of mesoporous silica as a porous carrier formulation technology to stabilize unstable polymorphs and to optimize solid state properties.
BioNTech Completes Acquisition of InstaDeep
BioNTech SE recently announced the completion of the acquisition of InstaDeep Ltd., a leading global technology company in the field of artificial intelligence (AI) and…
Bora Pharmaceuticals Unveils Eye-Opening New Facility for Ophthalmic Manufacturing
Bora Pharmaceuticals recently announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan. Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of….
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
PharmAla Biotech Holdings Inc. recently announced it has filed a patent on the composition of matter of PharmAla-1. The patent filing follows a year of preclinical…
WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations
Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs.
2023 Respiratory Drug Development eBook – Inhalers Trend Toward Sustainability & Targeted Control
In this fourth annual Respiratory e-book, learn more about Porex and Nemera and their contributions to inhalation drug delivery and device design.
First Wave BioPharma Announces Initial Topline Results From Phase 2 Trial Investigating Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced it has received topline results from its Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic….
George Medicines Completes Recruitment of first Phase 3 Hypertension Trial Investigating Novel Single-Pill Triple Combination Candidate
George Medicines recently announced all patients have been enrolled in its Phase 3 active-controlled trial evaluating the efficacy and safety of GMRx2, the company’s….
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
CENTOGENE N.V. recently announced the publication of a landmark study titled At a glance: the largest Niemann-Pick type C1 cohort with 602 patients diagnosed over…
NodThera is First to Demonstrate Reduction in Neuroinflammation in the Clinic With Brain Penetrant NLRP3 Inflammasome Inhibitor
NodThera recently announced positive, initial data from four subjects in the elderly volunteer stage of its Phase 1b/2a study evaluating the effects of its lead…
Ocean Biomedical’s mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential to Address Global & Emerging US Malaria Challenges
Ocean Biomedical, Inc. recently announced it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan Africa while recognizing newly emerging…
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
Akari Therapeutics, Plc recently announced updates on the development of long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA). Resulting from extensive preclinical development…
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
Daré Bioscience, Inc. and its collaborator Strategic Science & Technologies, LLC (SST) recently announced additional positive data from the exploratory Phase 2b RESPOND study evaluating…
